Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial

被引:1087
作者
Pollack, A
Zagars, GK
Starkschall, G
Antolak, JA
Lee, JJ
Huang, E
von Eschenbach, AC
Kuban, DA
Rosen, I
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Radiat Phys, Houston, TX 77030 USA
[3] Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[4] Univ Texas, MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 53卷 / 05期
关键词
radiotherapy; dose; prostate-specific antigen; rectal toxicity;
D O I
10.1016/S0360-3016(02)02829-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: A randomized radiotherapy dose escalation trial was undertaken between 1993 and 1998 to compare the efficacy of 70 vs. 78 Gy in controlling prostate cancer. Methods and Materials: A total of 305 Stage T1-T3 patients were entered into the trial and, of these, 301 with a median follow-up of 60 months, were assessable. Of the 301 patients, 150 were in the 70 Gy arm and 151 were in the 78 Gy arm. The primary end point was freedom from failure (FFF), including biochemical failure, which was defined as 3 rises in the prostate-specific antigen (PSA) level. Kaplan-Meier survival analyses were calculated from the completion of radiotherapy. The log-rank test was used to compare the groups. Cox proportional hazard regression analysis was used to examine the independence of study randomization in multivariate analysis. Results: There was an even distribution of patients by randomization arm and stage, Gleason score, and pretreatment PSA level. The FFF rates for the 70- and 78 Gy arms at 6 years were 64% and 70%, respectively (p = 0.03). Dose escalation to 78 Gy preferentially benefited those with a pretreatment PSA > 10 ng/mL; the FFF rate was 62% for the 78 Gy arm vs. 43% for those who received 70 Gy (P = 0.01). For patients with a pretreatment PSA less than or equal to10 ng/mL, no significant dose response was found, with an average 6-year FFF rate of about 75%. Although no difference occurred in overall survival, the freedom from distant metastasis rate was higher for those with PSA levels > 10 ng/mL who were treated to 78 Gy (98% vs. 88% at 6 years, p = 0.056). Rectal side effects were also significantly greater in the 78 Gy group. Grade 2 or higher toxicity rates at 6 years were 12% and 26% for the 70 Gy and 78 Gy arms, respectively (p = 0.001). Grade 2 or higher bladder complications were similar at 10%. For patients in the 78 Gy arm, Grade 2 or higher rectal toxicity correlated highly with the proportion of the rectum treated to >70 Gy. Conclusion: An increase of 8 Gy resulted in a highly significant improvement in FFF for patients at intermediate-to-high risk, although the rectal reactions were also increased. Dose escalation techniques that limit the rectal volume that receives greater than or equal to70 Gy to <25% should be used. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:1097 / 1105
页数:9
相关论文
共 36 条
[1]  
Amling CL, 1998, MAYO CLIN PROC, V73, P401
[2]   Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer - Preliminary results [J].
Bey, P ;
Carrie, C ;
Beckendorf, V ;
Ginestet, C ;
Aletti, P ;
Madelis, G ;
Luporsi, E ;
Pommier, P ;
Cowen, D ;
Gonzague-Casabianca, L ;
Simonian-Sauve, M ;
Maingon, P ;
Naudy, S ;
Lagrange, JL ;
Marcie, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 48 (02) :513-517
[3]  
COX DR, 1984, ANAL SURVIVAL DATA, P110
[4]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[5]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[6]   Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial [J].
Dearnaley, DP ;
Khoo, VS ;
Norman, AR ;
Meyer, L ;
Nahum, A ;
Tait, D ;
Yarnold, J ;
Horwich, A .
LANCET, 1999, 353 (9149) :267-272
[7]   Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer [J].
Gardner, BG ;
Zietman, AL ;
Shipley, WU ;
Skowronski, UE ;
McManus, P .
JOURNAL OF UROLOGY, 2002, 167 (01) :123-126
[8]   Cancer surveillance series: Interpreting trends in prostate cancer - Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates [J].
Hankey, BF ;
Feuer, EJ ;
Clegg, LX ;
Hayes, RB ;
Legler, JM ;
Prorok, PC ;
Ries, LA ;
Merrill, RM ;
Kaplan, RS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (12) :1017-1024
[9]   THE EFFECT OF DOSE ON LOCAL-CONTROL OF PROSTATE-CANCER [J].
HANKS, GE ;
MARTZ, KL ;
DIAMOND, JJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1988, 15 (06) :1299-1305
[10]   PATTERNS OF CARE STUDIES - DOSE-RESPONSE OBSERVATIONS FOR LOCAL-CONTROL OF ADENOCARCINOMA OF THE PROSTATE [J].
HANKS, GE ;
LEIBEL, SA ;
KRALL, JM ;
KRAMER, S .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1985, 11 (01) :153-157